Kornimate/medical-research-clean huggingface dataset:
blood flow restriction and creatine supplementation in women

Conditions: Physical Inactivity

Summary: this research is examining the changes in muscle size, muscle function, body composition, strength, and blood vessel health. specifically, the changes in these variables over the course of 8 weeks of training with or without blood flow restriction (bfr) and the supplementation of creatine or placebo (dextrose, a sugar in the form of a powder which is the standard placebo). creatine monohydrate (cr) is the most popular supplement for athletes and benefits all populations, however women are still very hesitant to take it due to the misconception of weight gain. this study will look to measure those muscle and body changes with exercise.

we expect that you will be in this research study for an estimated 10 weeks, with 27 visits total. you will be asked to complete questionnaires, blood draws, and perform exercises using exercise machines for testing the strength of your legs while using a blood pressure cuff during some of these exercises. other tests in this study will measure hydration (water in your system) status, your nervous system, and body composition percentage (bone/muscle tissue/fat tissue). specifically, you will be asked to attend: * 1 consent visit with familiarization (60min) * 1 baseline assessment with a blood sample (60min) * 1 baseline strength assessment (45min) * 2 creatine supplementation loading day visits (15min) * 1 post loading assessment with a blood sample (60min) * 1 post loading strength assessment (45min) * 16 training days (60min each) two of which will have blood samples (+70min) * 1-4wk follow up assessment (45min) * 1 4wk follow up strength assessment (45min) * 1 posttest assessment (45min) * 1 posttest strength assessment (45min)

Eligibility criteria:
inclusion criteria: * are female between the ages of 18 to 35 * recreationally active, defined as meeting the acsm standards for recreationally active individuals of participating in physical activity ≥ 150 minutes exercise/week. * not following a resistance training program * are not currently taking creatine monohydrate or have not taken it in the last 6 weeks * no known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease (i.e. heart failure, diabetes, copd, etc.) * do not regularly use prescription medication (not including contraceptives) * are not currently seeking medical care. * are not currently pregnant. exclusion criteria: * taking creatine or has taken creatine in the last 6 weeks * currently resistance training * pregnant

Keywords: creatine blood flow restriction exercise
clinical effectiveness of damon ultima vs conventional brackets trial)

Conditions: Skeletal and Dental CL I Malocclusion Moderate Crowding

Summary: compare the clinical performance, root resorption and pain perception between passive self-ligating damon ultema vs conventional brackets.

damon ultima system was introduced and claimed to be the first true full expression orthodontic system designed for faster and more precise finishing. the brackets were completely reengineered to virtually eliminate play for precise control of rotation, angulation and torque. moreover, the system used specially designed archwires regarding wire dimensions and shape to fulfill the manufacturers claim.

Eligibility criteria:
inclusion criteria: * 15-35 years of age patients who are healthy and without medications such as non-steroidal anti-inflammatory analgesics. * patients with class i normal occlusion with moderate dental irregularity (with 4-6 irregularity index) requiring non-extraction treatment. * presence of all the permanent teeth apart from the third molars. * patients with good oral hygiene and periodontal health. * without previous orthodontic treatment/ functional appliances exclusion criteria: patients will be excluded from recruitment if he had sever skeletal discrepancy that requires orthognathic surgery. • patients who have cleft lip or palate, hypodontia, or hyperdontia
effect of peri-operative immunonutrition on recurrence and infections in crohn's disease patients

Conditions: Crohn Disease

Summary: this is an interventional randomized ope-label two-arm trial on the peri-operative use of immunonutrition in crohn's disease (cd) patients undergoing colorectal elective surgery.the aim of the trial is to assess the effectiveness of immunonutrition therapy in decreasing the rate of post-operative infective complications and 6 months endoscopic disease recurrence.

crohn's disease (cd) patients undergoing abdominal surgery are at high risk to develop post-operative surgical and medical infective complications. infective complications affect almost 24% of patients. post-surgical disease recurrence afflicts 35-85% of cd patients in the first year after surgery. immunonutrition has been successfully applied to surgical patients in several randomized trials, demonstrating a decreased rate of post-operative infective complications. the aim of the study is to compare the incidence of surgical and medical post-operative infective complications and six months endoscopic and clinical disease recurrence (dr) in cd patients receiving immunonutrition in the peri-operative setting compared to patients treated as for standard of care.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old, females or males; * established crohn's disease at the time of surgery indication; * patients scheduled for elective open or minimally invasive bowel resection or strictureplasty; * patients planned for concomitant perianal surgery for cd-related perianal disease can be included in the study. exclusion criteria: * patients \< 18 years old; * pregnant or breastfeeding women; * diagnosis of undetermined colitis; * concomitant diagnosis of malignancy; * established malnutrition, according to clinical definition, requiring nutritional intervention; * patients with more than two criteria for high risk of recurrence among the following: previous abdominal resection, penetrating disease phenotype or active smoking; * any condition that, in the opinion of the investigator, can interfere with the consent procedure or the conduction of the trial; * patients known to have allergic history to any component of the investigational product; * patient with liver and kidney dysfunction (alanine aminotransferase alt ≥ 2 times the upper limit of normal; total bilirubin tbil ≥ 2 times the upper limit of normal; creatinine cr ≥ 2 times the upper limit of normal); * patients diagnosed with diabetes or fasting blood glucose≥ 10mmol/l; * planned recovery shorter than 48 hours; * surgery in emergency setting; * any concomitant surgery not related to cd or perianal cd.

Keywords: inflammatory bowel diseases crohn's disease immunonutrition
mri-based biomarkers for predicting punctate white matter lesions in neonates

Conditions: Brain Diseases; Amblyopia; Brain Damage, Chronic; Cerebral Palsy

Summary: as a common white matter (wm) disease in preterm neonates, punctate white matter lesion (pwml) frequently leads to the abnormalities of brain development (e.g. the motor, visual and auditory disorders), even to cerebral palsy (cp) and amblyopia during childhood. however, it is lack of certain methods in identifying the prognosis of pwml. through using various advanced mri techniques, neuro-behavioral and visual assessments, a multicenter longitudinal study would be conducted to follow-up the pwml neonates with varying spatial-position and degree lesions. through tracking the variations in wm microstructures from neonate period to childhood (2 years old and 3 years old), this study aims to explore (1) the potential relations between varying pwmls and motor and visual disorders (2) the relations between wm mri-metrics and neurodevelopmental assessment results, and thus determine the early biomarkers to identify cp and amblyopia.


Eligibility criteria:
inclusion criteria: -(1) age: 1-28 days (2) pwml (3) high quality mri scan exclusion criteria: -(1) congenital malformations, infections, metabolic disorders, intraventricular hemorrhage (2) neonates of mothers with gestational diabetes, hypertension, hypoglycemia and history of alcohol
night time walking to improve glycaemic control in healthy adults

Conditions: Postprandial Hyperglycemia; Insulin Resistance

Summary: randomised crossover trial to compare early vs late walking on postprandial glycaemic response at night time.

in this crossover trial, eligible participants will be randomised to a 30-minute bout of physical activity (30 minute walk) either during the day or after an evening meal. the postprandial response to the evening meal will be analysed.

Eligibility criteria:
inclusion criteria * men and women aged 18 to 65 years of age * waist circumference of \<94cm and \<80cm for caucasian males and females, respectively * waist circumference of \<90cm and \<80 cm for asian males and females, respectively * willingness to provide written informed consent and willingness to participate and comply with the study exclusion criteria * current or recent treatment (within 6 months) with medications that influence blood glucose * fasting blood glucose ≥ 7 mmol/l * individuals diagnosed with type 1 or type 2 diabetes mellitus, chronic gastrointestinal disorders (including inflammatory bowel disease and celiac) or any other condition deemed unstable * serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery * not able to walk for 30 mins at 5-5.5 km/hr * women planning pregnancy, pregnant or lactating.

Keywords: glucose tolerance meal timing insulin postprandial walking
sleepiness and the effects of cpap on salivary cortisol and alpha-amylase levels in patients with sleep apnea

Conditions: Sleep Apnea; Sleep Disordered Breathing

Summary: patients with obstructive sleep apnea syndrome (osas) will evidence higher levels of salivary cortisol and alpha-amylase levels prior to use of placebo and continuous positive airway pressure (cpap) and will evidence a decrease in these levels after consistent use of continuous positive airway pressure (cpap) therapy as compared to placebo. their level of sleepiness will also decrease with the use of cpap therapy and will correlate with the levels of salivary cortisol and alpha-amylase in relation to their subjective sleepiness scale, psychomotor vigilance test (pvt), and pupillometry.

it has been shown that there is an inconsistent response in serum cortisol levels in patients with obstructive sleep apnea syndrome (osas), but it is undetermined whether a change in hormone level was not seen due to compliance issues in these long-term studies. these investigators will be employing compliance monitoring continuous positive airway pressure (cpap) machines and also assessing "sleepiness" before and after therapy. sleepiness is the dependent variable in our study and will be measured subjectively using sleepiness scales and objectively using psychomotor vigilance test (pvt) and an autonomic measure using pupillometry prior, during and after treatment.

Eligibility criteria:
inclusion criteria: * adults * male and female * between ages 18 and 90 * undergo a polysomnography (psg) with evidence of any sleep disordered breathing including snoring, mild/moderate/severe sleep apnea, and/or restless legs exclusion criteria: * ages 17 and under * pregnant women

Keywords: automatic positive airway pressure (apap) continuous positive airway pressure (cpap) salivary cortisol apnea sleep apnea and/or any sleep disordered breathing
umbilical cord blood vs personalized treatments for improving autistic disorder

Conditions: Autistic Spectrum Disorder

Summary: the clinical study evaluates in an open-label, crossover design the comparative efficacy and safety of intranasal oxytocin and autologous umbilical cord blood for improving the functioning of children with autistic spectrum disorder

children aged 3-7 years diagnosed with autistic spectrum disorder and who did not previously receive oxytocin or umbilical cord blood treatments, will be enrolled to receive both treatments in random order. assessment of functioning impairment will be done with qchat/m-chat/cast questionnaires initially, at 2 months, 6 months and 1 year after first treatments. either oxytocin or cord blood will be administered initially and at visit 2, which will take place at 2 months. all children will receive both treatments. a total of 25-40 children are expected to enroll and complete the study.

Eligibility criteria:
inclusion criteria: * diagnosis of autistic spectrum disorder exclusion criteria: * metabolic or genetic disorder (ex storage disease, down, etc),
clinical pulmonary embolism

Conditions: Acute Pulmonary Embolism

Summary: to evaluate the clinical characteristics, risk factors, management and outcome of patients admitted e acute pulmonary embolism in chest diseases department and respiratory icu in assiut university hospital

pulmonary embolism (pe) occurs when there is a disruption to the flow of blood in the pulmonary artery or its branches by a thrombus that originated somewhere else. in deep vein thrombosis (dvt), a thrombus develops within the deep veins, most commonly in the lower extremities. pe usually occurs when a part of this thrombus breaks off and enters the pulmonary circulation. very rarely, pe can occur from the embolization of other materials into the pulmonary circulation such as air, fat, or tumor cells.risk factors can be classified as genetic and acquired. genetic risk factors include thrombophilia such as factor v leiden mutation, prothrombin gene mutation, protein c deficiency, protein s deficiency, hyperhomocysteinemia, among others. acquired risk factors include immobilization for prolonged periods (bed rest greater than three days, anyone traveling greater than 4 hours, whether by air, car, bus, or train), recent orthopedic surgery, malignancy, indwelling venous catheter, obesity, pregnancy, cigarette smoking, oral contraceptive pill use other predisposing factors for vte include: fracture of lower limb hospitalization for heart failure or atrial fibrillation/flutter within the previous three months hip or knee replacement major trauma history of previous venous thromboembolism central venous lines chemotherapy congestive heart failure or respiratory failure hormone replacement therapy oral contraceptive therapy postpartum period infection (specifically pneumonia, urinary tract infection, and hiv) cancer (highest risk in metastatic disease) thrombophilia bed rest greater than three days obesity pregnancy cancer carries a high risk for thrombus formation and hence, pe. pancreatic cancer, hematological malignancies, lung cancer, gastric cancer, and brain cancer carry the highest risk for vtthe most common symptoms of pe include the following: dyspnea, pleuritic chest pain, cough, hemoptysis, presyncope, or syncope. dyspnea may be acute and severe in central pe, whereas it is often mild and transient in small peripheral pe. in patients with preexisting heart failure or pulmonary disease, worsening dyspnea may be the only symptom. chest pain is a frequent symptom and is usually caused by pleural irritation due to distal emboli causing pulmonary infarction.

Eligibility criteria:
inclusion criteria: * patients above 18 years old and less than 75 year old exclusion criteria: * patients with chronic thromboembolism _patient less than 18 years old
population pharmacokinetic study based on quantitative pharmacology in patients with lenalidomide

Conditions: Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma

Summary: this is a non-intervention, prospective, open-label and observational clinical trial. the researchers plan to recruit at least 50 qualified patients. the main purpose of this study was to establish a population pharmacokinetic(ppk) model of lenalidomide and explore factors associated with the adverse events of lenalidomide from a pharmacokinetic(pk) perspective.

studies have found that there is significant interpatient variability in the plasma concentration of lenalidomide, and the pk parameters of lenalidomide do not affect its efficacy but may be correlated with its toxicity. therefore, the investigators plan to conduct a ppk study on lenalidomide to identify factors contributing to interpatient pk differences, thus refining regimens to mitigate its adverse reactions, in the hope of optimizing the clinical application of lenalidomide. at least 50 patients are planned to be included. it should be noted that the study does not interfere with the patients' treatment plans. except for the discomfort during blood sampling, patients will not be exposed to any risks.

Eligibility criteria:
inclusion criteria: * patients who are above the age of 18 * patients who receive lenalidomide treatment exclusion criteria: * patients have received other investigational systemic drugs * the clinical data are deemed insufficient * there appear other factors that rendered them ineligible.
insulin glargine v rosiglitazone as add-on therapy in patients failing sulfonylurea and metformin combination therapy

Conditions: Type 2 Diabetes Mellitus

Summary: to compare the glycemic control, as measured by hba1c, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus for at least one year; * continuous treatment with at least half maximally labeled dose of a sulfonylurea and at least 1000 mg metformin daily for at least three months ; * glycated hemoglobin between 7.5 and 11 % units, inclusive; * willingness to accept, and ability to inject insulin glargine therapy exclusion criteria: * stroke, mi, coronary artery bypass graft, percutaneous transluminal coronary angioplasty or angina pectoris within the last 12 months; * congestive heart failure requiring pharmacological treatment; * serum creatinine \> 1.5 mg/dl for males, or \> 1.4 mg/dl for females; * acute or chronic metabolic acidosis, including diabetic ketoacidosis; * planned radiological examinations requiring administration of contrasting agents; * clinical evidence of active liver disease, or serum alt 2.5 times the upper limit of the normal range; * history of hypoglycemia unawareness; * pregnancy or lactation; * failure to use adequate contraception (women of current reproductive potential only); * known hypersensitivity to insulin glargine, rosiglitazone or any of the components of insulin glargine rosiglitazone; * bmi \>25 kg/m2; * malignancy except basal cell carcinoma within the last five years; * history of substance or alcohol abuse within last two years, or current addiction to substance or alcohol abuse; * any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study; * incapability to comply with study procedures
safety study of cetuximab in combination with cisplatin and vinorelbine to treat advanced non-small cell lung cancer

Conditions: Lung Neoplasms; Carcinoma; Cancer of the Lung; Non-Small-Cell Lung Carcinoma

Summary: the purpose of the study is to determine if u.s. manufactured cetuximab can be safely used for the treatment of non-small cell lung cancer in combination with cisplatin and vinorelbine.


Eligibility criteria:
inclusion criteria: * non-small cell lung cancer (nsclc), stage iv (per the american joint committee on cancer (ajcc) staging manual, seventh edition) or recurrent disease following surgery and/or radiation therapy * evaluable or measurable disease * eastern cooperative oncology group (ecog) performance status of 0, 1 or 2 exclusion criteria: * uncontrolled central nervous system (cns) metastasis. * previous exposure to monoclonal antibodies, signal transduction inhibitors or epidermal growth factor receptor (egfr) targeting therapy * concurrent malignancy * prior chemotherapy for nsclc * pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2 * superior vena cava syndrome contra-indicating hydration * white blood cells (wbc) \< 3,000/mm³ * absolute neutrophile count (anc) \< 1,500/mm³ * platelet \< 100,000/mm³ * hemoglobin (hgb) \< 9.0 g/dl * total bilirubin \> 1.5 x upper limit of normal (uln). * aspartate aminotransferase (ast) or alanine-aminotransferase (alt) \> 5.0 x uln. * serum creatinine \>1.25 x uln and calculated creatinine clearance \<60ml/min
clinical outcome of extended-depth-of-focus trifocal intraocualr lens (triumf) implantation

Conditions: Presbyopia

Summary: clinical outcome of extended-depth-of-focus trifocal intraocualr lens (triumf) implantation


Eligibility criteria:
inclusion criteria: 1. adult at the age of 21 or older at the time of the pre-operative examination and willing to have surgery on their 2nd eye within 7-28 days of their 1st eye 2. age-related cataract 3. a patient with preoperative corneal astigmatism from iol master less than 1 diopters 4. a patient want presbyopia correction at the same time as cataract surgery 5. a patient has the visual potential of 20/25 or better in each eye after cataract removal and iol implantation 6. written informed consent to surgery and participation in the study exclusion criteria: 1. those with other diseases that can affect capsule stability such as pseudoexoliation syndrome, glaucoma, traumatic cataract 2. pregnant woman and lactating woman 3. a patient with history of ocular trauma or ocular surgery (intraocular surgery, refractive surgery, ocular surface surgery) in either eye 4. a patient with evidence of keratoconus or significant irregular astigmatism on pre-operative topography in either eye 5. if expectations for presbyopia correction are too high 6. those who are not able to read and understand the informed consent (illiterate or foreigners)

Keywords: depth and focus